share_log

StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com 开始报道阿亚拉制药(纳斯达克股票代码:ADXS)
Financial News Live ·  2023/03/18 01:32

Equities researchers at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a report issued on Friday. The firm set a "sell" rating on the stock.

StockNews.com的股票研究人员开始报道以下股票 阿亚拉制药(纳斯达克股票代码:ADXS — 获取评级) 在周五发布的一份报告中。该公司对该股设定了 “卖出” 评级。

Ayala Pharmaceuticals Stock Up 7.1 %

阿亚拉制药股价上涨7.1%

Shares of NASDAQ:ADXS traded up $0.10 during midday trading on Friday, reaching $1.51. The company's stock had a trading volume of 716 shares, compared to its average volume of 8,139. Ayala Pharmaceuticals has a 1 year low of $1.00 and a 1 year high of $10.80.

纳斯达克股票代码:ADXS的股价在周五午盘交易中上涨了0.10美元,达到1.51美元。该公司的股票交易量为716股,而平均交易量为8,139股。阿亚拉制药的1年低点为1.00美元,为1年高点10.80美元。

Get
获取
Ayala Pharmaceuticals
阿亚拉制药
alerts:
警报:

About Ayala Pharmaceuticals

关于阿亚拉制药

(Get Rating)

(获取评级)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

Advaxis, Inc是一家生物技术公司,从事癌症免疫疗法的发现、开发和商业化。它管理的平台技术利用活的减毒单核细胞增生李斯特菌分泌抗原或辅助融合蛋白。该公司拥有四个处于不同临床和临床前开发阶段的特许经营权,即:人乳头瘤病毒相关癌症、前列腺癌、新抗原疗法和热点突变疗法。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (ADXS)
  • This Small Tech With Big Growth Prospects Is Nearing A Buy Point
  • Don't Chase FedEx Higher, Wait For The Pullback
  • 3 Stocks For A Defensive Tech Portfolio
  • Milk the Dividends on These 3 Cash Cows
  • Europe Raises Interest Rates, Should the Fed Follow?
  • 免费获取 StockNews.com 关于阿亚拉制药(ADXS)的研究报告的副本
  • 这家具有巨大增长前景的小型科技公司已接近买入点
  • 不要追高联邦快递,等着回调
  • 防御性科技投资组合的3只股票
  • 在这 3 头摇钱树身上挤出股息
  • 欧洲提高利率,美联储应该效仿吗?

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收《阿亚拉制药日报》的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Ayala Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发